Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Nanovesicle-mediated delivery of anticancer agents effectively induced cell death and regressed intrahepatic tumors in athymic mice.

George J, Yan IK, Patel T.

Lab Invest. 2018 Jul;98(7):895-910. doi: 10.1038/s41374-018-0053-4. Epub 2018 May 10.

PMID:
29748614
2.
3.

The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC.

Choi J, Yip-Schneider M, Albertin F, Wiesenauer C, Wang Y, Schmidt CM.

J Surg Res. 2008 Dec;150(2):219-26. doi: 10.1016/j.jss.2008.01.029. Epub 2008 Mar 3.

PMID:
18468633
4.

Autophagy inhibition contributes to the synergistic interaction between EGCG and doxorubicin to kill the hepatoma Hep3B cells.

Chen L, Ye HL, Zhang G, Yao WM, Chen XZ, Zhang FC, Liang G.

PLoS One. 2014 Jan 21;9(1):e85771. doi: 10.1371/journal.pone.0085771. eCollection 2014.

5.

Enriching lipid nanovesicles with short-chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors.

van Lummel M, van Blitterswijk WJ, Vink SR, Veldman RJ, van der Valk MA, Schipper D, Dicheva BM, Eggermont AM, ten Hagen TL, Verheij M, Koning GA.

FASEB J. 2011 Jan;25(1):280-9. doi: 10.1096/fj.10-163709. Epub 2010 Sep 27.

PMID:
20876209
6.

Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.

Zhao X, Chen Q, Li Y, Tang H, Liu W, Yang X.

Eur J Pharm Biopharm. 2015 Jun;93:27-36. doi: 10.1016/j.ejpb.2015.03.003. Epub 2015 Mar 11.

PMID:
25770771
7.

Targeted doxorubicin nanotherapy strongly suppressing growth of multidrug resistant tumor in mice.

Nguyen DH, Lee JS, Bae JW, Choi JH, Lee Y, Son JY, Park KD.

Int J Pharm. 2015 Nov 10;495(1):329-335. doi: 10.1016/j.ijpharm.2015.08.083. Epub 2015 Sep 14.

PMID:
26325307
8.
9.

Targeted hepatocellular carcinoma therapy: transferrin modified, self-assembled polymeric nanomedicine for co-delivery of cisplatin and doxorubicin.

Zhang X, Li J, Yan M.

Drug Dev Ind Pharm. 2016 Oct;42(10):1590-9. doi: 10.3109/03639045.2016.1160103. Epub 2016 Mar 17.

PMID:
26942448
10.

Application of doxorubicin-induced rAAV2-p53 gene delivery in combined chemotherapy and gene therapy for hepatocellular carcinoma.

Chen CA, Lo CK, Lin BL, Sibley E, Tang SC.

Cancer Biol Ther. 2008 Feb;7(2):303-9. Epub 2007 Nov 21.

11.

Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma.

Zhou X, Zhang M, Yung B, Li H, Zhou C, Lee LJ, Lee RJ.

Int J Nanomedicine. 2012;7:5465-74. doi: 10.2147/IJN.S33965. Epub 2012 Oct 16.

12.

Doxorubicin loaded silica nanorattles actively seek tumors with improved anti-tumor effects.

Gao F, Li L, Liu T, Hao N, Liu H, Tan L, Li H, Huang X, Peng B, Yan C, Yang L, Wu X, Chen D, Tang F.

Nanoscale. 2012 Jun 7;4(11):3365-72. doi: 10.1039/c2nr12094a. Epub 2012 Apr 27.

PMID:
22538830
13.

Selenium-functionalized liposomes for systemic delivery of doxorubicin with enhanced pharmacokinetics and anticancer effect.

Xie Q, Deng W, Yuan X, Wang H, Ma Z, Wu B, Zhang X.

Eur J Pharm Biopharm. 2018 Jan;122:87-95. doi: 10.1016/j.ejpb.2017.10.010. Epub 2017 Oct 13.

PMID:
29032193
14.

A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.

Li Y, Yu DC, Chen Y, Amin P, Zhang H, Nguyen N, Henderson DR.

Cancer Res. 2001 Sep 1;61(17):6428-36.

15.

A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer.

Wen ZM, Jie J, Zhang Y, Liu H, Peng LP.

Biochem Biophys Res Commun. 2017 Dec 2;493(4):1430-1437. doi: 10.1016/j.bbrc.2017.09.132. Epub 2017 Sep 25.

PMID:
28958938
17.

Tumor targeting using anti-her2 immunoliposomes.

Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC.

J Control Release. 2001 Jul 6;74(1-3):95-113.

PMID:
11489487
18.

Water-soluble polymers for targeted drug delivery to human squamous carcinoma of head and neck.

Nan A, Ghandehari H, Hebert C, Siavash H, Nikitakis N, Reynolds M, Sauk JJ.

J Drug Target. 2005 Apr;13(3):189-97.

PMID:
16036307
19.

Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways.

Zheng T, Wang J, Song X, Meng X, Pan S, Jiang H, Liu L.

J Cancer Res Clin Oncol. 2010 Oct;136(10):1597-604. doi: 10.1007/s00432-010-0817-8. Epub 2010 Feb 20.

PMID:
20174822
20.

A human anti-c-Met Fab fragment conjugated with doxorubicin as targeted chemotherapy for hepatocellular carcinoma.

Chen X, Ding G, Gao Q, Sun J, Zhang Q, Du L, Qiu Z, Wang C, Zheng F, Sun B, Ni J, Feng Z, Zhu J.

PLoS One. 2013 May 13;8(5):e63093. doi: 10.1371/journal.pone.0063093. Print 2013.

Supplemental Content

Support Center